You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201371 - 201380 of 207726 results
  1. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 100

    PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of visual acuity in some patients but have no effect on other visual functions such as contrast sensitivity that are important for activities of daily life. Even with steroid treatments, 13,000 ON patie ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. PET Probes for Senescence Detection in Brain

    SBC: Senotrac Biotechnology LLC            Topic: NIA

    PROJECT SUMMARYAround 50 million people worldwide are suffering from Alzheimer’s disease (AD) and related dementias, and AD is observed primarily in aged people. Current diagnosis of AD relies primarily on observations of declines in mental and cognitive functions, when irreversible brain damage occurs. Positron emission tomography (PET) tracers for early diagnosis of AD have been developed via ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. The development of a multifunctional nanoenzyme for AD treatment

    SBC: AcePre, LLC            Topic: NIA

    Summary. The development of Alzheimer’s disease (AD) is the collective consequence of the toxicities induced by β-amyloid (Aβ) plaques, tau protein-formed neurofibrillary tangles, and malfunction of microglia due to inflammation and oxidative damage. Most AD therapeutics only target one of these key factors; the failed clinical trials proved the insufficiency of these individual approaches. In ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. AAV-AIBP Therapy for Alzheimer's Disease

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIA

    PROJECT SUMMARY Therapy for Alzheimer’s disease and related dementias (AD/ADRD), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (Aβ) removal from the brain or on targeting genes for which strong associations between their polymorphism and AD/ADRD are established, have had a mixed record of success. We propose a novel strategy to rev ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing mGlu1 positive allosteric modulators as therapeutics to facilitate abstinence in cocaine use disorder

    SBC: ELEUTHERIA PHARMACEUTICALS LLC            Topic: NIDA

    Project Summary A major challenge in treating cocaine use disorder is that vulnerability to cue-induced craving and relapse persist even after long periods of abstinence. There is presently no FDA-approved medication to lessen cocaine craving. The goal of Eleutheria Pharmaceuticals LLC is to develop metabotropic glutamate receptor 1 (mGlu1) positive allosteric modulators (PAMs) as therapeutic agen ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Early detection and monitoring of Alzheimers Disease and Related Dementias using non-semantic linguistic and acoustic features of speech derived from hearing aids

    SBC: BISCHOFF HOLDINGS INC            Topic: NIA

    Abstract Alzheimer’s disease and related dementias (ADRD) are a serious national health concern that affected 5.8 million in 2020 and are expected to increase by 40% over the next decade. There is evidence that the functional, psychological, pathological, and physiological changes underlying ADRD may emerge many years prior to the clinical manifestation of cognitive symptoms, which is increasing ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Hale: A Mobile-Connected Medical Vaporizer that Alleviates Nicotine Dependence

    SBC: HAVA HEALTH INC            Topic: NIDA

    PROJECT SUMMARY Cigarette smoking is a significant public health concern impacting 34 million adults in the USA by increasing their risk for cancer and cardiovascular disease, including 16 million living with chronic smoking-related diseases. National campaigns for smoking cessation have been promoted by public authorities, and other groups. In addition, pharmaceutical-grade nicotine replacement t ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. High Density Cooling System for Ultra-Low PUE Data Centers

    SBC: Impact Cooling LLC            Topic: NA

    Data center efficiency gains have effectively stalled over the past decade. Meanwhile, data centers are on track to consume 8% of global electricity by the year 2030 and approximately one-third of that energy is wasted on cooling server equipment rather than being used for actual computations. Despite the growing availability of liquid cooling solutions, due to their limited adoption, the primary ...

    SBIR Phase I 2022 Department of Energy
  10. High Density Cooling System for Ultra-Low PUE Data Centers

    SBC: Impact Cooling LLC            Topic: NA

    Data center efficiency gains have effectively stalled over the past decade. Meanwhile, data centers are on track to consume 8% of global electricity by the year 2030 and approximately one-third of that energy is wasted on cooling server equipment rather than being used for actual computations. Despite the growing availability of liquid cooling solutions, due to their limited adoption, the primary ...

    SBIR Phase II 2022 Department of Energy
US Flag An Official Website of the United States Government